| SOXS 1.8134 1.31% | TPET 1.0099 140.45% | ONDS 10.685 6.00% | STAK 0.7273 71.13% | NVDA 182.49 2.99% | TMDE 2.38 158.08% | TURB 1.195 76.93% | BITO 9.53 5.19% | XLE 56.825 1.62% | RYDE 0.3346 44.60% | EONR 0.4951 14.61% | NOK 8.31 7.64% | TZA 6.1006 -2.08% | BHAT 0.039 -21.21% | NVD 7.0729 -6.07% | IBIT 39.235 5.50% | USEG 1.1477 7.26% | TQQQ 49.77 0.50% | PLUG 1.7892 -0.04% | MSTX 2.4874 10.55% | TSLS 5.645 0.09% | AES 14.3 -17.25% | JDST 1.23 6.03% | AAL 12.53 -4.13% | PLTR 146.02 6.44% | BATL 10.45 89.31% | NFLX 97.185 0.98% | HYG 80.345 -0.46% | SQQQ 70.49 -0.51% | TSLL 14.645 -0.37% | QQQ 608.4 0.18% | SOFI 18.145 2.17% | MARA 9.485 6.10% | ETHA 15.38 5.92% | XLF 51.425 -0.01% | INTC 45.0699 -1.18% | NU 15.195 1.44% | IWM 263.25 0.70% | TLT 89.495 -1.46% | TSLA 401.9 -0.15% | BMNR 20.52 8.11% | CRCG 2.9598 23.33% | NIO 4.72 -3.08% | VG 11.12 14.76% | BYND 0.8594 -9.12% | BANL 0.6087 34.82% | BKLN 20.245 0.17% | RCAT 13.7841 18.32% | LQD 110.885 -0.71% | KOS 2.195 -5.79%

Raymond James Downgrades Weave on Timing of Catalysts and SMB Software Pressure

Raymond James downgraded Weave Communications (NYSE: WEAV) from Strong Buy to Outperform and lowered its price target to $10.00 from $12.00.

The firm said its longer-term thesis on Weave remained largely intact, but the rating change reflected the timing of expected catalysts and a more challenging environment for small and mid-sized business software companies. Raymond James noted that Weave continued to gain traction across several growth initiatives, including expansion into Specialty Medical, which had become its second-largest market by locations.

The analyst also pointed to progress in multi-office deployments, including a recently announced win covering more than 600 locations, and a growing pipeline for its AI receptionist and automation solution, TrueLark. Additional growth opportunities were seen through deeper integrations, improved product packaging, potential ARPC expansion via AI and payments offerings, and broader go-to-market partnerships.

While these initiatives were expected to take time to fully materialize, Raymond James said it still saw a path toward re-accelerating growth and a return to a more consistent beat-and-raise pattern. The firm added that although shares traded at just 2x its 2026 sales estimate, a full re-rating was unlikely until organic growth acceleration became more visible or the company demonstrated a clearer glide path toward long-term profitability.

Published on: January 6, 2026